Health Economics›Esophageal cancer›Adjuvant therapy

Adjuvant therapy

Esophageal cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 235	28d	—	~9.8 mo	~7	~R 8 648 PFS proxy · indirect	4
Placebo Partial	—	—	—	~3.0 mo	~6.7 mo	—	—	38
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~1.8 mo	~10.9 mo	~2	—	6

3 of 3 regimens shown